Clay Siegall is a biotechnology expert who is changing the lives of cancer patients in the world. He is the founder of a company known as Seattle Genetics. The biotechnology company was founded in the year 1998, and it has developed several therapies for cancer patients. The first product from the company is known as Adcetris, and it is already being used in the market. According to a recent report, the drug has helped to cure more than fifteen thousand cases of lymphoma in the world.
Clay Siegall currently works as the Chief Executive Officer and President of Seattle Genetics. He is also serving the board of directors as chairman. Under the leadership of Dr. Clay Siegall, Seattle Genetic is working hard to develop a diverse portfolio that will address clinical and preclinical products for the treatment of different types of cancers and other autoimmune diseases that affect people today.
Seattle Genetics is currently considered to be among the leaders in antibody technologies in the United States, especially in the antibody-drug conjugate platform. The success of the company is attributed to the experience and skills of their Chief Executive Officer, Clay Siegall. The well-known biotechnology expert is also behind the capital raising activities in Seattle Genetics. In a recent report, Siegall is believed to have helped the company raise over three hundred million in private and public financing.
This capital is going to be used in the development of better and safer drugs for the treatment of some of the most common cancers that affect many people today. According to Clay Siegall, the company will soon be introducing drugs for breast cancer. The company has also released a report stating that it will be increasing the number of employees to facilitate the new creation of more drugs.
Before starting Seattle Genetics, Clay Siegall was already working in the biotechnology industry. He once worked for Bristol-Myers, one of the most prominent companies in the United States. Clay has also had the opportunity to work for the National Cancer Institute too. Mirna Therapeutics also appointed Clay Siegall to work as the outside director on the board of directors. Clay got this position because of his massive experience in cancer treatment.